The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

Authors:
  • ARAline Renneville
    Aline Renneville
  • EMElizabeth MacIntyre
    Elizabeth MacIntyre
  • SMSamuel Mastrilli
    Samuel Mastrilli
  • FAFelix Ackermann
    Felix Ackermann
  • JCJean Michel Cayuela
    Jean Michel Cayuela
  • PRPhilippe Rousselot
    Philippe Rousselot
  • ASAline Schmidt-Tanguy
    Aline Schmidt-Tanguy
  • OFOlivier Fain
    Olivier Fain
  • MMMarc Michel
    Marc Michel
  • JJJean-Pierre de Jaureguiberry
    Jean-Pierre de Jaureguiberry
  • PHPierre-Yves Hatron
    Pierre-Yves Hatron

Abstract
Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P+ CEL patients identified in the French Eosinophil Network and treated with imatinib. The most frequently involved systems were skin (57%), spleen (52%), and lung (45%), and eosinophilic heart disease was observed in 15 patients (34%). Complete hematologic response (CHR) was obtained in all patients, and complete molecular response (CMR) in 95% of patients (average initial imatinib dose, 165 mg/d). For 29 patients the imatinib dose was tapered with a maintenance dose of 58 mg/d (±34 mg/d), allowing sustained CHR and CMR. None of the patients developed resistance during a median follow-up of 52.3 months (range, 1.4–97.4 mo). Imatinib was stopped in 11 patients; 6 of the patients subsequently relapsed, but 5 remained in persistent CHR or CMR (range, 9–88 mo). These results confirm that an initial low-dose regimen of imatinib (100 mg/d) followed by a lower maintenance dose can be efficient for obtaining long-term CHR and CMR. Our data also suggest that imatinib can be stopped in some patients without molecular relapse.

This publication has 31 references indexed in Scilit: